LDL-C

Low-density lipoprotein cholesterol (LDL-C) is the cholesterol carried inside LDL particles and the most familiar number on any lipid panel. It is a useful but limited cardiovascular risk marker: in most adults it tracks closely with ApoB, but in people with small dense LDL particles, high triglycerides, or metabolic syndrome, LDL-C systematically underestimates true atherogenic risk. The contemporary view is that ApoB is the better number; LDL-C remains the default because every lab in the world reports it.

Optimal range

Range varies by individual.

Test frequency

Annually as part of routine cardiovascular surveillance; every three to six months during an active lipid-management intervention (statin titration, dietary change, weight loss).

When to measure

Measure on every annual lipid panel from age 30 onward, earlier if there is family history of premature coronary disease or any familial dyslipidemia. Always pair with ApoB, lipoprotein(a) at least once in a lifetime, triglycerides, and a hemoglobin A1c so that the LDL-C value is interpreted in metabolic context. Fast 12 hours for accuracy of the triglyceride and calculated LDL-C; direct LDL-C measurement does not require fasting but is less commonly ordered.

How to measure

Standard lipid panel via venous blood draw; LDL-C is typically calculated by the Friedewald or Martin-Hopkins equation from total cholesterol, HDL-C, and triglycerides. Cost is $20–$60 retail. Direct LDL-C measurement is available for $30–$80 and is preferred when triglycerides are above 400 mg/dL, where the calculated value becomes unreliable. NMR LipoProfile reports LDL particle number alongside LDL-C and is the cleanest single test.

Why this biomarker matters

LDL particles are the dominant vehicle for cholesterol delivery to peripheral tissues and the principal carrier of atherogenic lipid into the arterial wall. Cumulative lifetime exposure to LDL, area under the LDL-versus-time curve, is now widely accepted as causal for atherosclerosis on the strength of Mendelian randomization (PCSK9, NPC1L1, HMGCR variants) and dozens of randomized trials of statins, ezetimibe, and PCSK9 inhibitors. The reason LDL-C alone is incomplete is that two people with the same LDL-C can carry very different particle numbers. Someone with high triglycerides and small dense LDL has many more atherogenic particles per unit of LDL cholesterol than someone with large buoyant LDL at the same LDL-C. That is precisely the population in which LDL-C underestimates risk. Optimal LDL-C for primary prevention in adults at standard risk is generally under 100 mg/dL; for those with established disease or very high lifetime risk (family history, high Lp(a), diabetes), most contemporary lipidologists target under 70 mg/dL or even under 55 mg/dL.

The prime report

Weekly performance intelligence.

New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.